145 related articles for article (PubMed ID: 7250897)
1. Studies of cell-mediated immunity in patients with Crohn's disease.
Surrenti C; Ramarli D; Casini A; Scartabelli S; Campi P; Fani A; Nieri S
Hepatogastroenterology; 1981 Jun; 28(3):157-9. PubMed ID: 7250897
[TBL] [Abstract][Full Text] [Related]
2. Induction of impaired activation of lymphocytes by suppressive factor in Crohn's disease patients.
Watanabe M; Tsuru S; Aiso S; Hibi T; Yoshida T; Asakura H; Zinnaka Y; Tsuchiya M
J Clin Lab Immunol; 1984 May; 14(1):29-34. PubMed ID: 6748044
[TBL] [Abstract][Full Text] [Related]
3. [Selected cellular immunity parameters in patients with Lesniowski-Crohn disease].
Słotwiński R; Szczygieł B; Lech G; Kolewska D; Wasik M
Pol Merkur Lekarski; 1997 Nov; 3(17):224-7. PubMed ID: 9523477
[TBL] [Abstract][Full Text] [Related]
4. Crohn's disease, serum immunodepressive factors and circulating immune complexes.
Krc I; Kojecky Z; Matousková I; Benysek L
Boll Ist Sieroter Milan; 1980; 59(6):619-24. PubMed ID: 7236362
[TBL] [Abstract][Full Text] [Related]
5. [Status of cellular immunity in patients with Crohn's disease].
Auer IO; Ziemer E; Sommer H; Malchow H; Ehms H
Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():841-4. PubMed ID: 306176
[No Abstract] [Full Text] [Related]
6. Indomethacin sensitive suppressor cells in Crohn's disease: a possible role in decreased lymphocyte responsiveness.
Victorino RM
J Clin Lab Immunol; 1983 Aug; 11(4):197-201. PubMed ID: 6230454
[TBL] [Abstract][Full Text] [Related]
7. BCG treatment of Crohn's disease.
Rahban S; Sherman JH; Opelz G; Conley DR; Panish JF; Marks JW; Terasaki PI; Schoenfield LJ
Am J Gastroenterol; 1979 Feb; 71(2):196-201. PubMed ID: 373425
[TBL] [Abstract][Full Text] [Related]
8. Immunological studies on Crohn's disease. II. Lack of evidence for humoral and cellular dysfunctions.
Fujita K; Okabe N; Yao T
J Clin Lab Immunol; 1985 Mar; 16(3):155-61. PubMed ID: 3162025
[TBL] [Abstract][Full Text] [Related]
9. Preliminary investigation on humoral and cellular immune responses to selected food proteins in patients with Crohn's disease.
Frieri M; Claus M; Boris M; Zitt M; Scalise D; Harris N
Ann Allergy; 1990 Apr; 64(4):345-51. PubMed ID: 2321808
[TBL] [Abstract][Full Text] [Related]
10. Reduced suppressor cell activity in intestinal lymphocytes from patients with Crohn's disease.
Goodacre RL; Bienenstock J
Gastroenterology; 1982 Apr; 82(4):653-8. PubMed ID: 7060886
[TBL] [Abstract][Full Text] [Related]
11. Suppression of immunoglobulin synthesis by lymphocyte subpopulations in patients with Crohn's disease.
James SP; Neckers LM; Graeff AS; Cossman J; Balch CM; Strober W
Gastroenterology; 1984 Jun; 86(6):1510-8. PubMed ID: 6232165
[TBL] [Abstract][Full Text] [Related]
12. The mechanism of action of serum immunosuppressive factor in Crohn's disease: it blocks the growth of mitogen-stimulated lymphocytes in early G1 phase through an inhibition of transferrin receptor expression.
Iwao Y; Hibi T; Watanabe M; Takaishi H; Hosoda Y; Hayashi A; Ohara M; Ogata H; Aiso S; Toda K
J Clin Lab Immunol; 1992; 38(1):15-27. PubMed ID: 1343345
[TBL] [Abstract][Full Text] [Related]
13. The effect of azathioprine on cell-mediated immunity (CMI) to Candida albicans in Crohn's disease.
Gyte GM; Willoughby JM
Clin Exp Immunol; 1977 Nov; 30(2):242-51. PubMed ID: 342153
[TBL] [Abstract][Full Text] [Related]
14. Release of the serum immunosuppressive factor by monocytes in patients with Crohn's disease.
Watanabe M; Hibi T; Iwao Y; Kanai T; Ohara M; Fujisawa T; Ogata H; Watanabe N; Asakura H; Aiso S
J Clin Lab Immunol; 1989 Aug; 29(4):161-6. PubMed ID: 2637362
[TBL] [Abstract][Full Text] [Related]
15. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease.
Caradonna L; Amati L; Lella P; Jirillo E; Caccavo D
Am J Gastroenterol; 2000 Jun; 95(6):1495-502. PubMed ID: 10894586
[TBL] [Abstract][Full Text] [Related]
16. Differential levels of granzyme B, regulatory cytokines, and apoptosis in Crohn's disease and ulcerative colitis at first presentation.
Jenkins D; Seth R; Kummer JA; Scott BB; Hawkey CJ; Robins RA
J Pathol; 2000 Feb; 190(2):184-9. PubMed ID: 10657017
[TBL] [Abstract][Full Text] [Related]
17. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
18. [Changes in cell-mediated immune reactions in Crohn's disease].
Ecker KW; Güremen A; Feifel G
Z Gastroenterol; 1991 Oct; 29(10):529-32. PubMed ID: 1685823
[TBL] [Abstract][Full Text] [Related]
19. [Immunological parameters in Crohn's disease].
Krc I; Kojecký Z; Benýsek L; Matousková I
Cas Lek Cesk; 1978 Jun; 117(24):733-7. PubMed ID: 679247
[No Abstract] [Full Text] [Related]
20. Appearance of killer (K) cells in the mesenteric lymph nodes in Crohn's disease.
Britton S; Eklund AE; Bird AG
Gastroenterology; 1978 Aug; 75(2):218-20. PubMed ID: 669207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
